These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28260595)

  • 1. A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
    Bunyoz KI; Krarup H; Weis N
    Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm].
    Terrier B; Pol S; Thibault V; Gottenberg JE; Cacoub P;
    Rev Med Interne; 2012 Jan; 33(1):4-12. PubMed ID: 21889826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hospital-Based Analysis in the Department of Clinical Chemistry for the Patients with HBV Reactivation after Anti-Cancer or Immunosuppressive Therapy.
    Matsuzaki T; Ohkubo K; Yuki M; Kawashima H; Matsunaga A
    Rinsho Byori; 2015 Mar; 63(3):297-304. PubMed ID: 26524851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy.
    Stine JG; Bass M; Ibrahim D; Khokhar OS; Lewis JH
    South Med J; 2011 Dec; 104(12):781-8. PubMed ID: 22089354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatitis B reactivation following immunosuppressive therapy and screening adherence: a neglected problem?].
    Borde JP; Kern WV; Becker J; Bertz H; Hübner J; Offensperger WB
    Dtsch Med Wochenschr; 2012 Jul; 137(28-29):1458-62. PubMed ID: 22760404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.
    Tran TT; Rakoski MO; Martin P; Poordad F
    Aliment Pharmacol Ther; 2010 Jan; 31(2):240-6. PubMed ID: 19814747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
    Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
    Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening.
    Visram A; Chan KK; McGee P; Boro J; Hicks LK; Feld JJ
    PLoS One; 2015; 10(4):e0120749. PubMed ID: 25875198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy.
    Köksal AS; Toka B; Eminler AT; Hacıbekiroğlu I; Sunu C; Uslan MI; Karabay O; Parlak E
    Acta Gastroenterol Belg; 2019; 82(2):279-284. PubMed ID: 31314189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reactivation of Hepatitis B Virus and Guidelines for Its Prevention].
    Tsubouchi H
    Rinsho Byori; 2015 Sep; 63(9):1046-51. PubMed ID: 26731892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.
    Mindikoglu AL; Regev A; Schiff ER
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1076-81. PubMed ID: 16861051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.
    Lubel JS; Testro AG; Angus PW
    Intern Med J; 2007 Oct; 37(10):705-12. PubMed ID: 17894766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
    Sato K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening practices for hepatitis B virus prior to viral reactivation risk therapies among different medical specialties. HEBRA Project].
    García-Bengoechea M; Hernández-López C; Crespo J; Gea F;
    Med Clin (Barc); 2012 Nov; 139(11):498-501. PubMed ID: 22982126
    [No Abstract]   [Full Text] [Related]  

  • 15. [Rheumatoid arthritis and viral hepatitis].
    Kobayashi H; Watanabe H; Ohira H
    Nihon Rinsho; 2016 Jun; 74(6):1007-11. PubMed ID: 27311193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatitis B tests as screenings for the reactivation of HBV infection at Fukuoka University Hospital].
    Matsuzaki T; Ohkubo K; Kawashima H; Matsunaga A
    Rinsho Byori; 2011 Jun; 59(6):559-64. PubMed ID: 21815477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
    Phipps C; Chen Y; Tan D
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):5-11. PubMed ID: 26705677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk Management of HBV Reactivation: Construction of Check System].
    Tanaka Y
    Rinsho Byori; 2015 Sep; 63(9):1052-9. PubMed ID: 26731893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
    Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
    Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
    Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.